abstract |
The present invention relates to novel high-permeability compositions (HPCs) or high-permeability prodrugs (HPPs) of peptides and peptide-related compounds that are capable of crossing the biological barrier with high permeability in contrast to the parent drug. HPP can be converted to a parent drug or drug metabolite after crossing the biological barrier to treat conditions that can be treated with the parent drug or metabolite. In addition, HPP / HPC enables new treatment by allowing its parent drug to reach a site that is inaccessible or at a sufficient concentration. HPP / HPC can be administered to a subject via various routes of administration, for example, can be delivered locally at high concentrations to a site of pathological action or can be systemically administered to a biological subject and introduced into the large circulation at a rapid rate. Peptide HPP / HPC solid-phase synthesis has been developed from the N-terminus to the C-terminus. |